| Autor: |
Kyriazoglou, Anastasios, Kaparelou, Maria, Goumas, Georgios, Liontos, Michael, Zakopoulou, Roubini, Zografos, Eleni, Zygogianni, Anna, Dimopoulos, Meletios Athanasios, Zagouri, Flora |
| Předmět: |
|
| Zdroj: |
Breast Care; 2022, Vol. 17 Issue 1, p63-70, 8p |
| Abstrakt: |
Introduction: The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data. Methods: We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer. Results: Twelve clinical trials and 2 case reports were identified in our study. Conclusion: The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
